• Je něco špatně v tomto záznamu ?

Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease

P. Kapoor, MA. Dimopoulos, SM. Ansell, E. Kastritis, R. Advani, E. Durot, P. Morel, C. Kyriakou, R. Hajek, D. Drandi, JP. Abeykoon, S. Chow, X. Cao, CJ. Patterson, JV. Matous, C. Buske, SP. Treon, MJ. Kersten

. 2025 ; 62 (2) : 90-105. [pub] 20250408

Jazyk angličtina Země Spojené státy americké

Typ dokumentu konsensus - konference, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25016195

The Consensus Panel 3 (CP3) of the 12th International Workshop on Waldenström macroglobulinemia (IWWM-12) has reviewed and incorporated current data to make recommendations for the management of patients with high-risk WM (HR-WM). Recognizing the considerable heterogeneity in survival outcomes and identifying a subgroup of patients with a very poor prognosis, the key recommendations from CP3 include: (1) Risk stratifying patients with smoldering WM (SWM) and active (symptomatic) WM at diagnosis (2) Using the degree of i) bone marrow lymphoplasmacytosis, ii) serum beta-2 microglobulin (β2M) elevation, iii) IgM increase, iv) serum albumin decrease and the presence of wild-type MYD88 status markers that adversely dictate the time-to-progression from smoldering to active WM to the define HR-SWM. (3) Among patients with active WM, the presenting parameters: advanced chronological age, low serum albumin, elevated serum lactate dehydrogenase, elevated β2M and the presence of TP53 alterations (TP53 mutation or deletion 17p) unfavorably impact the prognosis and should be utilized to risk-stratify patients into the HR category. (4) The panel encourages screening for genetic alterations at diagnosis, prior to initiating therapy and also with rapidly advancing disease or refractoriness to ongoing therapy, which might result from clonal evolution. Although limited data directing the selection and sequencing of therapies exist, a risk-adapted approach and clinical trial participation for patients with HR-WM are highly encouraged.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016195
003      
CZ-PrNML
005      
20250731091606.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1053/j.seminhematol.2025.04.001 $2 doi
035    __
$a (PubMed)40441983
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kapoor, Prashant $u Mayo Clinic, Rochester MN. Electronic address: kapoor.prashant@mayo.edu
245    10
$a Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease / $c P. Kapoor, MA. Dimopoulos, SM. Ansell, E. Kastritis, R. Advani, E. Durot, P. Morel, C. Kyriakou, R. Hajek, D. Drandi, JP. Abeykoon, S. Chow, X. Cao, CJ. Patterson, JV. Matous, C. Buske, SP. Treon, MJ. Kersten
520    9_
$a The Consensus Panel 3 (CP3) of the 12th International Workshop on Waldenström macroglobulinemia (IWWM-12) has reviewed and incorporated current data to make recommendations for the management of patients with high-risk WM (HR-WM). Recognizing the considerable heterogeneity in survival outcomes and identifying a subgroup of patients with a very poor prognosis, the key recommendations from CP3 include: (1) Risk stratifying patients with smoldering WM (SWM) and active (symptomatic) WM at diagnosis (2) Using the degree of i) bone marrow lymphoplasmacytosis, ii) serum beta-2 microglobulin (β2M) elevation, iii) IgM increase, iv) serum albumin decrease and the presence of wild-type MYD88 status markers that adversely dictate the time-to-progression from smoldering to active WM to the define HR-SWM. (3) Among patients with active WM, the presenting parameters: advanced chronological age, low serum albumin, elevated serum lactate dehydrogenase, elevated β2M and the presence of TP53 alterations (TP53 mutation or deletion 17p) unfavorably impact the prognosis and should be utilized to risk-stratify patients into the HR category. (4) The panel encourages screening for genetic alterations at diagnosis, prior to initiating therapy and also with rapidly advancing disease or refractoriness to ongoing therapy, which might result from clonal evolution. Although limited data directing the selection and sequencing of therapies exist, a risk-adapted approach and clinical trial participation for patients with HR-WM are highly encouraged.
650    _2
$a lidé $7 D006801
650    _2
$a beta-2-mikroglobulin $x krev $7 D001613
650    _2
$a konsensus $7 D032921
650    _2
$a management nemoci $7 D019468
650    _2
$a prognóza $7 D011379
650    12
$a Waldenströmova makroglobulinemie $x terapie $x diagnóza $x genetika $x krev $7 D008258
655    _2
$a konsensus - konference $7 D016446
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dimopoulos, Meletios A $u Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University, Seoul, South Korea
700    1_
$a Ansell, Stephen M $u Mayo Clinic, Rochester MN
700    1_
$a Kastritis, Efstathios $u Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
700    1_
$a Advani, Ranjana $u Stanford University Medical Center, Stanford CA
700    1_
$a Durot, Eric $u Department of Hematology, University Hospital of Reims and UFR Médecine, Reims, France
700    1_
$a Morel, Pierre $u Department of Hematology, University Hospital of Amiens, Amiens, France
700    1_
$a Kyriakou, Charalampia $u Department of Haemato-Oncology, St Bartholomew's Hospital, London, UK
700    1_
$a Hajek, Roman $u Department of Haemato-oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Drandi, Daniela $u Department of Molecular Biotechnology and Health Sciences, Hematology Division, University of Torino, Italy
700    1_
$a Abeykoon, Jithma P $u Mayo Clinic, Rochester MN
700    1_
$a Chow, Signy $u Odette Cancer Centre, Sunnybrook Health Sciences Centre, Division of Medical Oncology and Hematology, Faculty of Medicine, University of Toronto, Toronto, Canada
700    1_
$a Cao, Xinxin $u National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
700    1_
$a Patterson, Christopher J $u Dana Farber Cancer Institute, Harvard Medical School, Boston MA
700    1_
$a Matous, Jeffrey V $u Colorado Blood Cancer Institute, Sarah Cannon Research Institute, Denver, CO
700    1_
$a Buske, Christian $u University Hospital Ulm, Institute of Experimental Cancer Research, Ulm, Germany
700    1_
$a Treon, Steven P $u Dana Farber Cancer Institute, Harvard Medical School, Boston MA
700    1_
$a Kersten, Marie J $u Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam/LYMMCARE, Amsterdam, the Netherlands
773    0_
$w MED00004323 $t Seminars in hematology $x 1532-8686 $g Roč. 62, č. 2 (2025), s. 90-105
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40441983 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091600 $b ABA008
999    __
$a ok $b bmc $g 2366793 $s 1253320
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 62 $c 2 $d 90-105 $e 20250408 $i 1532-8686 $m Seminars in hematology $n Semin Hematol $x MED00004323
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace